SIGA Technologies, Inc. announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company?s Board of Directors. SIGA?s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. As CEO, Dr. Nguyen will lead SIGA?s ongoing efforts in the development, manufacture and global distribution of antiviral therapies for the treatment of infectious diseases including smallpox, mpox, and other diseases associated with orthopox viruses.

Additionally, she will represent SIGA in engagements with government partners in the U.S. and internationally, playing a pivotal role in securing new contracts and partnerships. Dr. Nguyen joins SIGA from Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases, including pain associated with osteoarthritis, and neurodegenerative diseases, where she served as CEO. Prior to Xalud, Dr. Nguyen served as executive vice president of biopharma at PPD Inc., a leading global clinical research organization providing integrated drug development services.

From 2009-2018, she served in several roles at Pfizer including global president, Americas, Pfizer Essential Health, where she was responsible for diverse commercial businesses in the U.S., Latin America, Canada, and Puerto Rico representing more than $11 billion in annual revenue. She earned a Ph.D. in biochemistry and molecular genetics at the University of Virginia, as well as an M.B.A. from Darden Graduate School of Business Administration.